University of Genoa, San Martino Hospital and National Institute for Cancer Research, Department of Obstetrics and Gynecology, Largo R. Benzi 1, 16132 Genoa, Italy.
Expert Opin Biol Ther. 2013 May;13(5):739-64. doi: 10.1517/14712598.2013.767328. Epub 2013 Feb 4.
Despite aggressive debulking surgery, intraperitoneal therapies and the use of new drugs for chemotherapy, patients with ovarian cancer (OC) still have poor prognosis and, therefore, new strategies for its management are needed. Molecular-targeted agents can be considered a new option in drug research. Several antigens related to OC have been isolated and they could be potential target of monoclonal antibodies (mAbs); therefore, different mAbs have been developed and are emerging as new potential OC treatments.
This article aims to review the literature on the use of mAbs in the treatment of OC. The purposes of this manuscript are to offer a brief explanation of the mechanisms of action of mAbs and to help readers in understanding the current role of mAbs in the treatment of OC.
A deeper knowledge of the molecular biology of OC has brought new developments in targeted therapies. Among these therapies, bevacizumab demonstrated the higher clinical efficacy. Further larger trials are needed to better define the role of the other mAbs in OC treatment. There is a strong need to identify and validate robust biomarkers for a more focused patient selection and for tailoring therapies, optimizing dose and assessing response.
尽管进行了积极的肿瘤减灭术、腹腔内治疗和使用新的化疗药物，卵巢癌（OC）患者的预后仍然较差，因此需要新的治疗策略。分子靶向药物可被视为药物研究的一个新选择。已经分离出与 OC 相关的几种抗原，它们可能是单克隆抗体（mAb）的潜在靶点；因此，已经开发出不同的 mAb，并作为治疗 OC 的新的潜在方法不断涌现。
本文旨在综述 mAb 在 OC 治疗中的应用文献。本文的目的是简要解释 mAb 的作用机制，并帮助读者了解 mAb 在 OC 治疗中的当前作用。
对 OC 的分子生物学的更深入了解带来了靶向治疗的新进展。在这些治疗方法中，贝伐单抗显示出更高的临床疗效。需要进一步进行更大规模的试验，以更好地确定其他 mAb 在 OC 治疗中的作用。强烈需要识别和验证强大的生物标志物，以进行更有针对性的患者选择和治疗定制，优化剂量并评估反应。
